drugset / Trial / NCT02292186
A Extension Study to Evaluate Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Cardiac Amyloidosis
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study was to evaluate the safety and clinical activity of long-term dosing with revusiran (ALN-TTRSC). Dosing has been discontinued; patients are being followed-up for safety.
Timeline
- Start
- 2014-10
- Primary completion
- 2017-02-22
- Completion
- 2017-02-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Revusiran | Small interfering RNA (siRNA) | — | — |
Indications
No indication recorded.